QRG Capital Management Inc. Sells 7,866 Shares of Zoetis Inc. $ZTS

QRG Capital Management Inc. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 10.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,875 shares of the company’s stock after selling 7,866 shares during the period. QRG Capital Management Inc.’s holdings in Zoetis were worth $10,224,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC lifted its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. REAP Financial Group LLC raised its stake in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the last quarter. NewSquare Capital LLC lifted its holdings in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. ORG Partners LLC boosted its position in shares of Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after buying an additional 84 shares during the last quarter. Finally, Financial Consulate Inc. bought a new stake in Zoetis in the 3rd quarter worth about $39,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.4%

NYSE ZTS opened at $124.79 on Friday. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $54.99 billion, a P/E ratio of 21.01, a price-to-earnings-growth ratio of 2.53 and a beta of 0.97. The stock’s 50-day moving average price is $123.21 and its 200-day moving average price is $139.49.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the company posted $1.58 EPS. The firm’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is 35.69%.

Analysts Set New Price Targets

ZTS has been the topic of several research analyst reports. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a research note on Monday, December 15th. KeyCorp began coverage on Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating for the company. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Finally, HSBC set a $140.00 price target on Zoetis in a research note on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.